Transplant Anesthesia and Critical Care Unit, University School of Medicine, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy.
Liver Transplant Surgery Unit, University School of Medicine, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy.
BMC Anesthesiol. 2020 Jan 30;20(1):31. doi: 10.1186/s12871-020-0945-x.
Jehovah's Witnesses represent a tremendous clinical challenge when indicated to liver transplantation because they refuse blood transfusion on religious grounds and the procedure is historically associated with potential massive peri-operative blood loss. We herein describe a peri-operative management pathway with strategies toward a transfusion-free environment with the aim not only of offering liver transplant to selected Jehovah's Witnesses patients but also, ultimately, of translating this practice to all general surgical procedures.
This is a retrospective review of prospective medical records of JW patients who underwent LT at our Institution. The peri-operative multimodal strategy to liver transplantation in Jehovah's Witnesses includes a pre-operative red cell mass optimization package and the intra-operative use of normovolemic haemodilution, veno-venous bypass and low central venous pressure.
In a 9-year period, 13 Jehovah's Witness patients received liver transplantation at our centre representing the largest liver transplant program from deceased donors in Jehovah's Witnesses patients reported so far. No patient received blood bank products but 3 had fibrinogen concentrate and one tranexamic acid to correct ongoing hyper-fibrinolysis. There were 4 cases of acute kidney injury (one required extracorporeal renal replacement treatment) and one patient needed vasoactive medications to support blood pressure for the first 2 postoperative days. Two patients underwent re-laparotomy. Finally, of the 13 recipients, 12 were alive at the 1 year follow-up interview and 1 died due to septic complications.
Our experience confirms that liver transplantation in selected Jehovah's Witnesses patients can be feasible and safe provided that it is carried out at a very experienced centre and according to a multidisciplinary approach.
由于拒绝输血的宗教原因,当需要进行肝移植时,耶和华见证派教徒代表着巨大的临床挑战,而该手术历史上与潜在的大量围手术期失血有关。我们在此描述了一种围手术期管理途径,其中包括旨在实现无输血环境的策略,目的不仅是为选定的耶和华见证派教徒患者提供肝移植,而且最终将这种做法推广到所有普通外科手术。
这是对在我们机构接受 LT 的 JW 患者的前瞻性病历进行的回顾性研究。针对耶和华见证派教徒进行肝移植的围手术期多模式策略包括术前红细胞质量优化方案以及术中使用等容血液稀释、静脉-静脉旁路和低中心静脉压。
在 9 年期间,我们中心有 13 名耶和华见证派教徒接受了肝移植,这是迄今为止报道的来自已故供体的耶和华见证派教徒中最大的肝移植计划。没有患者接受血库产品,但有 3 名患者接受了纤维蛋白原浓缩物和 1 名患者接受了氨甲环酸来纠正持续的高纤维蛋白溶解。有 4 例急性肾损伤(1 例需要体外肾脏替代治疗)和 1 例患者在术后前两天需要血管活性药物来维持血压。2 名患者需要再次剖腹手术。最终,在 13 名受者中,12 名在 1 年随访访谈时存活,1 名因感染性并发症死亡。
我们的经验证实,只要在经验丰富的中心并采用多学科方法进行,选择合适的耶和华见证派教徒患者进行肝移植是可行且安全的。